Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer

Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Rainer Porschen(Klinikum Bremen-Mitte), Axel Grothey(Campbell Clinic), Werner Freier(Mayo Clinic in Florida), Thomas Seufferlein(Universität Ulm), Ullrich Graeven(Kliniken Maria Hilf), Axel Hinke, Christina Englisch-Fritz(Klinikum Bremen-Mitte), Wolff Schmiegel(Universitätsklinikum Knappschaftskrankenhaus Bochum), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), S. Kubicka(Mayo Clinic in Florida), Albrecht Kretzschmar(Roche (Switzerland)), Richard Greil(Paracelsus Medical University)
Clinical Colorectal Cancer
January 1, 2008
10.3816/ccc.2008.n.009
Cited by 30

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k